Insider · SEC Form 4 filer
Jon Kayyem
Companies
Where they file as an insider
Inhibrx Biosciences (INBX) Director Latest filing Sep 23, 2026
Inhibrx (INBX) Director Latest filing May 30, 2024
Track record
Did their buys beat the typical stock?
Open-market buys12
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check1
Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.
Inhibrx Biosciences (INBX) Bought Sep 8–23, 2026 · $1.57M · 15,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Inhibrx Biosciences (INBX) Bought Nov 19–20, 2024 · $762K · 53,593 shares Behind typical Dec 31, 2024 $15.40 → Jun 30, 2025 $14.27 · −7.3% (typical stock −3.4%)
Inhibrx Biosciences (INBX) Bought May 31–Jun 5, 2024 · $5.92M · 344,335 shares Beat typical Jun 30, 2024 $14.17 → Dec 31, 2024 $15.40 · +8.7% (typical stock +3.9%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.